Pharma Journalist -

Eli Lilly and Company and UnitedHealth Group announced a partnership to conduct a pragmatic study of bamlanivimab (LY-CoV555) in high-risk, COVID-19 infected individuals.…
Read More...

Y-mAbs Therapeutics, Inc. a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment…
Read More...

Tevard Biosciences, a privately-held biotechnology company pioneering tRNA-based gene therapies, and Zogenix, a global biopharmaceutical company developing and commercializing rare…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has approved Gavreto (pralsetinib) for the treatment of adult and paediatric patients 12 years of age and older with…
Read More...

Neurogene Inc., a company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, announces that the European Medicines Agency…
Read More...

Appili Therapeutics Inc. a biopharmaceutical company focused on anti-infective drug development, announced  that investigators have dosed the first participant in its Phase 3 trial…
Read More...

Merck KGaA, Darmstadt, Germany, a leading science and technology company and Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of…
Read More...

Roche announced that its Elecsys Anti-SARS-CoV-2 S antibody test has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). The serology (blood)…
Read More...

Exelixis, Inc., Iconic Therapeutics, Inc. (Iconic) and Zymeworks Inc. announced that Exelixis has exercised its exclusive option for Iconic’s lead oncology antibody-drug conjugate (ADC)…
Read More...

The U.S. government has purchased 650,000 additional doses of Eli Lilly and Company's (NYSE: LLY) neutralizing antibody bamlanivimab (LY-CoV555) 700 mg. The purchase agreement is for…
Read More...